• E-mail
• Print
• Comment
• Font Size
• Digg
• del.icio.us
• Discuss article

Cortex Pharmaceuticals' CEO Participates in the Life Science Mission to Israel

Posted on: Thursday, 7 July 2005, 09:00 CDT

Roger Stoll, Ph.D., President and CEO of Cortex Pharmaceuticals, Inc. (AMEX: COR), was one of 50 leaders from the U.S. in the health sciences field invited to participate in the Life Science Mission to Israel during the last week of June. The mission was sponsored by The New Jerusalem Foundation, the Jerusalem Development Authority and Global Capital Associates. This group of U.S. healthcare leaders in academia, industry and capital markets met with numerous venture groups, industry, and academic, and government leaders from Israel to explore potential opportunities for relationships with their U.S. counterparts. Dr. Stoll was one of nine participants to receive the Albert Einstein Award for Outstanding Achievements in the Life Sciences at a ceremony on June 29th in Jerusalem.

The Albert Einstein Award for Outstanding Achievement in the Life Sciences salutes path-breaking leaders whose vision and commitment have contributed to the critical advancement of vital life-saving and life-enhancing technology to the benefit of mankind. It also has been previously awarded to leaders in the IT field.

Over his 30-year career, Dr. Stoll has distinguished himself as a leader in general management, research and development, manufacturing, business development and strategic planning in the pharmaceutical and medical products industry.

About Cortex Pharmaceuticals

Cortex, located in Irvine, California, is a neuroscience company focused on novel drug therapies for neurological and psychiatric disorders. The Company is pioneering a class of proprietary pharmaceuticals called AMPAKINE compounds, which act to increase the strength of signals at connections between brain cells. The loss of these connections is thought to be responsible for memory and behavior problems in Alzheimer's disease. Many psychiatric diseases, including schizophrenia, occur as a result of imbalances in the brain's neurotransmitter system. These imbalances may be improved by using the AMPAKINE technology. Cortex has alliances with N.V. Organon for the treatment of schizophrenia and depression and with Les Laboratoires Servier for the development of AMPAKINE compounds to treat the neurodegenerative effects associated with aging and disease, including Mild Cognitive Impairment, Alzheimer's disease and anxiety disorders. (http://www.cortexpharm.com/)

Forward-Looking Statement

Note - This press release contains forward-looking statements concerning the Company's research and development activities. The success of such activities depends on a number of factors, including the risks that the Company's proposed compounds may at any time be found to be unsafe or ineffective for the indications under clinical test and that clinical studies may at any point be suspended or take substantially longer than anticipated to complete. As discussed in the Company's Securities and Exchange Commission filings, the Company's proposed products will require additional research, lengthy and costly clinical testing and regulatory approval. AMPAKINE compounds are investigational drugs and have not been approved for the treatment of any disease.

Source: Business Wire

More News in this Category